Jade Biosciences, Inc.

What they do

Jade Biosciences discovers and develops novel monoclonal antibody therapies for autoimmune diseases, aiming to improve dosing, convenience, safety, and clinical activity over existing treatments. Its lead candidate, JADE101, targets APRIL and is in development for IgA nephropathy; JADE201 targets BAFF-R for multiple autoimmune disorders; and JADE301 targets an undisclosed pathway, now disclosed in the August 2026 earnings release as anti-IFN- for dermatomyositis. The company is headquartered in Waltham, Massachusetts and had 63,597,387 shares outstanding as of August 3, 2026.

Revenue drivers

• JADE101 (anti-APRIL mAb for IgA nephropathy) — Lead product candidate; no revenue to date. The company plans a Phase 3 registrational trial in the first half of 2027, pending FDA feedback.
• JADE201 (anti-BAFF-R mAb) — Second product candidate; no revenue to date. A Phase 1 trial in rheumatoid arthritis began dosing, with interim data expected in 2027.
• JADE301 (anti-IFN- mAb for dermatomyositis) — Third product candidate, formerly JADE-003; no revenue to date. Phase 1 healthy volunteer trial now expected in the fourth quarter of 2026.

Recent performance

For the second quarter of 2026, Jade reported cash, cash equivalents, and investments of $461 million as of June 30, 2026, expected to provide runway into the fourth quarter of 2028. The company announced positive interim Phase 1 results for JADE101, showing mean IgA reductions of approximately 70% from baseline after a single 700 mg dose and support for every 12-week subcutaneous dosing. Annual net loss widened to $127.4 million in 2025 from $69.6 million in 2024, and operating cash flow was negative $94.7 million in 2025. Diluted EPS was negative $3.19 in 2025. Total assets were $472.1 million and total liabilities $32.2 million as of June 30, 2026.

Strategy

Jade's stated strategy is to advance JADE101 in IgA nephropathy, with a Phase 2 trial underway and a Phase 3 registrational trial expected to begin in the first half of 2027 pending FDA feedback. The company is also advancing JADE201 into the clinic for multiple autoimmune disorders and JADE301 toward a Phase 1 trial in dermatomyositis ahead of plan. JADE301 is designed as a half-life extended anti-IFN- antibody for subcutaneous administration at extended intervals. The company aims to leverage preclinical differentiation, including increased potency and extended half-life, to pursue best-in-class profiles.

Risks

• No approved products or revenue — The company has no products approved for commercial sale, has not generated revenue from product candidates, and may never become profitable.
• Substantial additional capital required — Jade will require substantial additional capital to finance operations; if unable to raise capital when needed, it may delay, reduce, or eliminate development programs.
• Clinical and regulatory uncertainty — All programs are in clinical or preclinical stages, and the company has not completed any clinical trials; future trial results, including JADE101 Phase 2 and JADE201 Phase 1, may not replicate interim findings.
• Competition — Jade faces competition from entities that have developed or may develop products for the diseases addressed by its product candidates, including other anti-APRIL and B cell-targeting therapies.

Outlook

Management expects interim Phase 2 data for JADE101 in IgA nephropathy in 2027 and plans to initiate a Phase 3 registrational trial in the first half of 2027 pending FDA feedback. JADE201 Phase 1 interim biomarker-rich data are expected in 2027 and will inform indication prioritization. JADE301 Phase 1 initiation in healthy volunteers is now expected in the fourth quarter of 2026, with interim data anticipated in the second half of 2027. The company states its $461 million in cash, cash equivalents, and investments as of June 30, 2026 is expected to fund operations into the fourth quarter of 2028.